AKR1C3 and breast carcinoma: Aldo–keto reductase 1C3 (AKR1C3) is also linked to doxorubicin resistance in human breast cancer which resulted from activation of anti-apoptosis PTEN/Akt pathway via PTEN loss (Zhong et al., 2015).